Experiment Design: ER-Golgi Secretory Pathway Dysfunction in [Parkinson's Disease](/diseases/parkinsons-disease)
Experiment Overview
Mermaid diagram (expand to render)
Objective: Validate the ER-Golgi Secretory Pathway Dysfunction Hypothesis in [Parkinson's Disease](/diseases/parkinsons-disease) by testing whether:
ER-Golgi dysfunction precedes [alpha-synuclein](/proteins/alpha-synuclein) aggregation in [dopaminergic neurons](/cell-types/dopaminergic-neurons)
Genetic risk factors ([GBA](/genes/gba), [VPS35](/genes/vps35), ATP13A9) cause ER-Golgi impairment
ER-Golgi modulators can prevent or reverse dopaminergic neurodegenerationStudy Design: Multi-phase, multi-arm translational study
Duration: 36 months (12 months per phase)
Phase 1: In Vitro Validation (Months 1-12)
Study 1.1: iPSC-Derived Dopaminergic Neuron Characterization
Objective
Characterize ER-Golgi function in dopaminergic neurons derived from PD patients with various genetic backgrounds.
Methods
Patient Cohorts:
- Group 1: [GBA](/genes/gba) mutation carriers (n=5)
- Group 2: [LRRK2](/genes/lrrk2) G2019S carriers (n=5)
- Group 3: [VPS35](/genes/vps35) D620N carriers (n=3)
- Group 4: Sporadic [PD](/diseases/parkinsons-disease) (n=5)
- Group 5: Healthy controls (n=5)
Primary Endpoints:
| Endpoint | Method | Timepoint |
|----------|--------|-----------|
| ER stress markers | Western blot: p-PERK, p-eIF2α, CHOP, BiP | Day 0, 30, 60 |
| Golgi integrity | GM130 immunostaining + confocal microscopy | Day 0, 30, 60 |
| XBP1 splicing | qRT-PCR | Day 0, 30, 60 |
| [Alpha-synuclein](/proteins/alpha-synuclein) aggregation | pSer129-αSyn IHC | Day 0, 30, 60 |
| Viability | ATP assay + caspase 3/7 | Day 0, 30, 60 |
Secondary Endpoints:
- Mitochondrial function: Seahorse XF analysis
- Autophagy flux: LC3 II turnover
- Calcium homeostasis: Fluo-4 AM imaging
- Synaptic function: Synaptophysin/VGLUT2 puncta analysis
Sample Size Justification
Using ANOVA with 5 groups, α=0.05, power=0.80, effect size=0.5, requires n=3 minimum per group. Using n=5 for robustness.
Study 1.2: Toxin Model Time Course
Objective
Determine temporal relationship between ER-Golgi dysfunction and alpha-synuclein aggregation following toxin exposure.
Methods
Treatment Groups:
- Vehicle control
- MPTP (1μM, 24h)
- 6-OHDA (100μM, 24h)
- Rotenone (10nM, 72h)
- Paraquat (10μM, 72h)
Cell Type: iPSC-derived dopaminergic neurons (n=3 lines per group)
Timepoints: 2h, 6h, 12h, 24h, 48h, 72h post-treatment
Readouts:
Early markers (<6h):
- ER calcium depletion (Fluo-5F AM)
- p-PERK activation (Western blot)
- Golgi dispersion (GM130 staining)
Intermediate markers (6-24h):
- XBP1 splicing
- CHOP expression
- p-eIF2α
Late markers (24-72h):
- Alpha-synuclein pSer129
- Mitochondrial complex I activity
- Cell viability
Statistical Analysis
Mixed-effects model with treatment × time interaction. Post-hoc Bonferroni correction.
Study 1.3: Therapeutic Intervention In Vitro
Objective
Test whether ER-Golgi modulators protect dopaminergic neurons from toxin-induced degeneration.
Methods
Intervention Arms:
| Compound | Dose | Mechanism | Source |
|----------|------|-----------|--------|
| TUDCA | 200μM | Chemical chaperone | Sigma-Aldrich |
| Guanabenz | 10μM | eIF2α phosphatase inhibitor | MedChemExpress |
| Salubrinal | 10μM | eIF2α phosphatase inhibitor | Selleck Chemicals |
| ISRIB | 5μM | ATF4 pathway modulator | Tocris |
| Vehicle | — | — | — |
Toxicity Challenge: MPTP 1μM for 24h (pre-treatment with compounds 1h prior)
Readouts: Cell viability, ER stress markers, Golgi integrity, alpha-synuclein aggregation
Analysis: IC50 determination, synergy assessment (Comburent analysis)
Phase 2: In Vivo Validation (Months 12-24)
Study 2.1: Mouse Model Characterization
Objective
Validate ER-Golgi dysfunction in established mouse models of PD.
Models
MPTP mouse model (C57BL/6, 8 weeks, male)
α-Synuclein transgenic (SNCA A53T, Jackson Labs)
GBA knockout (conditional in neurons)
VPS35 D620N knock-inExperimental Design
MPTP Model:
- Acute: MPTP 30mg/kg × 5 days, sacrifice day 1, 3, 7, 14
- Chronic: MPTP 20mg/kg × 4 weeks, sacrifice week 1, 4, 8, 12
- Controls: Saline-treated age-matched
Readouts:
- Behavioral: Rotarod, cylinder, gait analysis (pre and post)
- Histological: TH+ neuron count, pSer129-αSyn, IBA1 (microglia), GFAP (astrocytes)
- Molecular: ER stress PCR array, Golgi integrity, mitochondrial complex I
- Biochemical: Striatal dopamine, CSF biomarkers
Sample Size: n=12 per group (power 0.80, effect size 0.8)
Study 2.2: Pharmacological Intervention In Vivo
Objective
Test whether ER-Golgi modulators rescue dopaminergic neurons in vivo.
Methods
Treatment Groups (n=12 per group):
Vehicle (saline, i.p.)
MPTP + TUDCA (250mg/kg, i.p., daily)
MPTP + Guanabenz (2mg/kg, i.p., daily)
MPTP + Salubrinal (1mg/kg, i.p., daily)
Positive control: MPTP + CoQ10 (100mg/kg, i.p., daily)Treatment Protocol:
- Pre-treatment: 7 days
- Co-treatment with MPTP: 14 days
- Post-treatment observation: 28 days
Endpoints:
- Primary: TH+ neuron survival in substantia nigra pars compacta
- Secondary: Rotarod performance, striatal dopamine levels
- Exploratory: ER stress markers (qPCR), Golgi morphology (EM)
Phase 3: Clinical Translation (Months 24-36)
Study 3.1: Biomarker Validation
Objective
Identify and validate ER-Golgi pathway biomarkers in PD patients.
Study Design
Prospective cohort study
Cohorts:
- Early PD (n=50, H&Y 1-2)
- Advanced PD (n=50, H&Y 3-4)
- Prodromal RBD (n=30)
- Healthy controls (n=30)
Biomarker Candidates:
| Biomarker | Source | Method | Pathway |
|----------|--------|--------|---------|
| BiP/GRP78 | CSF | ELISA | ER chaperone |
| XBP1s mRNA | PBMCs | qRT-PCR | UPR activation |
| p-PERK | Blood cells | Western blot | UPR activation |
| GM130 | Exosomes | Western blot | Golgi integrity |
| TUDCA | Urine | LC-MS | ER stress (metabolite) |
Correlation Analysis:
- UPDRS motor score
- Dopamine transporter imaging (DAT-SPECT)
- CSF alpha-synuclein
- Disease duration
Study 3.2: Proof-of-Concept Clinical Trial
Objective
Assess safety and preliminary efficacy of TUDCA in early PD patients.
Design
Randomized, double-blind, placebo-controlled
Population: Early PD (H&Y 1-2, n=60)
Arms (n=20 each):
TUDCA 500mg BID oral
TUDCA 1000mg BID oral
PlaceboDuration: 52 weeks
Endpoints:
- Primary: Safety (adverse events)
- Secondary: Change in UPDRS Part III, MoCA, CSF biomarkers
- Exploratory: ER stress markers in blood, DAT-SPECT change
Statistical Analysis Plan
Primary Analysis
Mixed-effects models for repeated measures, with treatment as fixed effect, subject as random effect, baseline as covariate.
Multiple Comparison Correction
Bonferroni for primary endpoints, FDR for exploratory endpoints.
Power Calculations
- In vitro: n=5 per group, power >0.80 for effect size 1.0
- In vivo: n=12 per group, power >0.80 for effect size 0.8
- Clinical: n=20 per group, power >0.80 for effect size 0.6
Success Criteria
Phase 1 Success
- ≥70% of patient-derived neurons show elevated ER stress markers
- Time-course demonstrates ER-Golgi dysfunction precedes α-syn aggregation
- ≥1 compound shows ≥50% neuroprotection in vitro
Phase 2 Success
- Mouse models confirm ER-Golgi dysfunction in vivo
- ≥1 compound shows ≥30% neuron rescue vs. MPTP alone
- Behavioral improvements correlate with molecular markers
Phase 3 Success
- Biomarker panel shows significant difference between PD and controls
- TUDCA shows acceptable safety profile
- Trend toward clinical benefit (UPDRS improvement ≥3 points)
Data Management
- Electronic data capture (REDCap)
- Centralized biobank (CSF, blood, tissue)
- Blind coding for all experimental groups
- Independent statistical review
Ethical Considerations
- IRB approval for all human studies
- IACUC approval for animal studies
- Informed consent for patient cohorts
- Data safety monitoring board for clinical trial
References
Hetz C, et al., Targeting ER stress in neurodegeneration. Nat Rev Drug Discov. 2023 (2023)
Saxena S, et al., ER stress in Parkinson's disease. J Neurochem. 2018 (2018)
Zhao Y, et al., Golgi fragmentation in neurodegeneration. J Neurosci Res. 2018 (2018)
Matus S, et al., TUDCA in neurodegeneration. Pharmacol Res. 2016 (2016)
Lindholm D, et al., ER stress and apoptosis. Cell Mol Life Sci. 2006 (2006)See Also
- [HMGB1 — High Mobility Group Box 1](/wiki/genes-hmgb1) — biomarker_for